Pemazyre
Payments companies reported to CMS as associated with Pemazyre. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pemazyre, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pemazyre
These are the largest totals companies reported as associated with Pemazyre. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mohamad Khair Khasawneh | Maywood, IL | Hematology & Oncology | $181,718.46 |
| Gina Vaccaro | Cookeville, TN | Medical Oncology | $108,281.71 |
| Joshua Strauss | Springfield, NJ | Hematology & Oncology | $71,275.55 |
| Milind Javle | Houston, TX | Hematology & Oncology | $70,705.37 |
| Amit Mahipal | Rochester, MN | Medical Oncology | $57,694.56 |
| Michael Morse | Durham, NC | Hematology & Oncology | $56,254.29 |
| Chih-Yi Liao | Chicago, IL | Hematology & Oncology | $50,312.07 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $46,752.64 |
| Gabriel Schwartz | San Francisco, CA | Family | $46,156.34 |
| Richard Kim | Tampa, FL | Hematology & Oncology | $40,167.77 |
Prescribed Pemazyre?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.